Considerations with Newer Regimens for Indolent Non–Hodgkin Lymphoma

Rummel, Mathias

doi:10.3816/clm.2008.s.008

Clinical Lymphoma and Myeloma

2008

DOI: 10.3816/clm.2008.s.008

|View full text |Cite

Considerations with Newer Regimens for Indolent Non–Hodgkin Lymphoma

Mathias Rummel

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2014

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here we report use of bendamustine plus idarubicin in older patients with newly‐diagnosed AML and high‐risk myelodysplastic syndrome (MDS). Bendamustine may function both as an alkylating agent and a nucleoside analogue and has been effective in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma (Rummel, ,b; Cheson & Rummel, ). The drug may be associated with prolonged myelosuppression, a characteristic suggesting utility in AML (Strupp et al , ).…”

mentioning

confidence: 99%

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

et al. 2014

View full text Add to dashboard Cite

Combinations of agents may improve outcomes among elderly acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) patients. We performed an adaptive phase I/II trial for newly-diagnosed AML or high-risk MDS patients aged ≥ 50 years using a Bayesian approach to determine whether 1 of 3 doses of bendamustine (45, 60, 75 mg/m2 days 1–3), together with idarubicin (12 mg/m2 days 1–2), might provide a complete response (CR) rate ≥ 40% with <30% grade 3–4 non-haematological toxicity. We treated 39 patients (34 AML; 5 MDS with >10% marrow blasts; median age 73 years). None of the 3 bendamustine doses in combination with idarubicin met the required CR and toxicity rates; the 75 mg/m2 dose because of excess toxicity (2 of 3 patients) and the 60 mg/m2 dose because of low efficacy (CR rate 10/33), although no grade 3–4 non-haematological toxicity was seen at this dose. Median survival was 7.2 months. All patients began treatment as outpatients but hospitalization was required in 90% (35/39). Although we did not find a dose of bendamustine combined with idarubicin that would provide a CR rate of >40% with acceptable toxicity, bendamustine may have activity in AML/MDS patients, suggesting its addition to other regimens may be warranted.

show abstract

mentioning

confidence: 99%

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

et al. 2014

View full text Add to dashboard Cite

show abstract

Novel treatment regimens for Waldenström’s macroglobulinemia

Ocio

2010

Expert Review of Hematology

View full text Add to dashboard Cite

Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder defined by bone marrow infiltration by lymphoplasmacytic cells as defined by the current classification systems. According to its transition situation between mutated chronic lymphocytic leukemia and multiple myeloma, several new therapeutic alternatives have been proposed for this entity based on the experience with these two well-known conditions together with the highly singular data provided by preclinical models. Thus, in WM two main therapeutic attitudes are possible: the use of conventional therapies based on the administration of single drugs or combinations with alkylating agents, purine analogues and anti-CD20 monoclonal antibodies; or the use of very new combinations that, without rejecting the previously mentioned drugs, include new agents, such as proteasome inhibitors, immunomodulatory agents or even histone deacetylase inhibitors and PI3K/AKT inhibitors, among others. Here we review the most recent results reported for the use of new combinations and new drugs in patients with WM at different stages of the disease.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Considerations with Newer Regimens for Indolent Non–Hodgkin Lymphoma

Cited by 2 publications

References 56 publications

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design

Novel treatment regimens for Waldenström’s macroglobulinemia

Contact Info

Product

Resources

About